{"id":3236,"date":"2026-04-10T08:29:13","date_gmt":"2026-04-10T05:29:13","guid":{"rendered":"https:\/\/merkezlaboratuvari.com\/test-listesi\/total-psa-prostat-spesifik-antijen-total-2\/"},"modified":"2026-04-21T12:38:44","modified_gmt":"2026-04-21T09:38:44","slug":"total-psa-prostat-spesifik-antijen-total","status":"publish","type":"page","link":"https:\/\/merkezlaboratuvari.com\/ar\/test-listesi\/total-psa-prostat-spesifik-antijen-total\/","title":{"rendered":"Total PSA (Prostat Spesifik Antijen Total)"},"content":{"rendered":"<h1>Total PSA (Prostat Spesifik Antijen Total)<\/h1>\n<h2>Laboratuvar Bilgileri<\/h2>\n<ul>\n<li><strong>Yeni Kod:<\/strong> BIO6090<\/li>\n<li><strong>SUT Kodu:<\/strong> L106280<\/li>\n<li><strong>Eski Kod:<\/strong> HR0067<\/li>\n<li><strong>Kategori:<\/strong> \u0643\u064a\u0645\u064a\u0627\u0621 \u062d\u064a\u0648\u064a\u0629<\/li>\n<li><strong>Numune T\u00fcr\u00fc:<\/strong> Serum<\/li>\n<li><strong>Numune Kab\u0131:<\/strong> Sar\u0131 Kapak<\/li>\n<li><strong>\u00c7al\u0131\u015fma G\u00fcn\u00fc:<\/strong> Her g\u00fcn<\/li>\n<li><strong>\u00d6nemli Kriter:<\/strong> \u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r.<\/li>\n<li><strong>Raporlama Tarihi:<\/strong> Ayn\u0131 g\u00fcn 18:00<\/li>\n<\/ul>\n<h2>Total PSA (Prostat Spesifik Antijen Total) Testi Nedir?<\/h2>\n<p>Total PSA (Prostat Spesifik Antijen Total), laboratuvar ortam\u0131nda de\u011ferlendirilen bir biyokimya testidir. De\u011ferlendirme \u00e7o\u011fu zaman serum \u00f6rne\u011fi \u00fczerinden planlan\u0131r.<\/p>\n<p>PSA (Prostat Spesifik Antijen), prostat bezi epitel h\u00fccreleri taraf\u0131ndan \u00fcretilen bir serin proteazd\u0131r. Seminal s\u0131v\u0131n\u0131n s\u0131v\u0131la\u015fmas\u0131nda g\u00f6rev al\u0131r. Kanda d\u00fc\u015f\u00fck d\u00fczeylerde bulunur ve prostat kanserinin tan\u0131, tarama ve takibinde en yayg\u0131n kullan\u0131lan t\u00fcm\u00f6r belirtecidir. Total PSA, serbest ve ba\u011fl\u0131 PSA&#8217;n\u0131n toplam\u0131n\u0131 ifade eder.<\/p>\n<p>Bu testin klinik anlam\u0131; istem nedeni, hastan\u0131n yak\u0131nmalar\u0131, ya\u015f\u0131, e\u015flik eden hastal\u0131klar\u0131, kullan\u0131lan y\u00f6ntem ve di\u011fer laboratuvar bulgular\u0131 ile birlikte de\u011ferlendirilir. Bu nedenle sonu\u00e7, tek ba\u015f\u0131na de\u011fil, b\u00fct\u00fcnc\u00fcl t\u0131bbi \u00e7er\u00e7eve i\u00e7inde yorumlanmal\u0131d\u0131r.<\/p>\n<h2>Total PSA (Prostat Spesifik Antijen Total) Hangi Durumlarda \u0130stenir?<\/h2>\n<p>Total PSA (Prostat Spesifik Antijen Total) testi, hekim taraf\u0131ndan klinik gereklilik g\u00f6r\u00fclen durumlarda istenebilir. \u0130stem gerek\u00e7esi hastan\u0131n mevcut tablosuna g\u00f6re de\u011fi\u015febilir.<\/p>\n<ul>\n<li>Prostat kanseri taramas\u0131 (\u00f6zellikle 50 ya\u015f \u00fcst\u00fc erkeklerde)<\/li>\n<li>Prostat kanseri riski y\u00fcksek bireylerde erken tarama (aile \u00f6yk\u00fcs\u00fc olanlarda 40-45 ya\u015f\u0131ndan itibaren)<\/li>\n<li>Prostat kanseri tedavi yan\u0131t\u0131n\u0131n izlenmesi<\/li>\n<li>Radikal prostatektomi veya radyoterapi sonras\u0131 n\u00fcks takibi<\/li>\n<li>Benign prostat hiperplazisi (BPH) takibi<\/li>\n<li>Parmakla rektal muayene (DRM) ile birlikte prostat de\u011ferlendirmesi<\/li>\n<\/ul>\n<p>Ayn\u0131 test farkl\u0131 hastalarda farkl\u0131 klinik sorulara yan\u0131t aramak amac\u0131yla kullan\u0131labildi\u011fi i\u00e7in, nihai de\u011ferlendirme her zaman ki\u015fisel t\u0131bbi \u00f6yk\u00fc ve muayene bulgular\u0131 ile birlikte yap\u0131lmal\u0131d\u0131r.<\/p>\n<h2>Total PSA (Prostat Spesifik Antijen Total) Testi \u00d6ncesi Haz\u0131rl\u0131k<\/h2>\n<p>Haz\u0131rl\u0131k gereksinimi; testin t\u00fcr\u00fcne, numune yap\u0131s\u0131na ve laboratuvar\u0131n \u00e7al\u0131\u015fma kurallar\u0131na g\u00f6re de\u011fi\u015febilir. Test \u00f6ncesinde laboratuvar\u0131n ve hekimin verdi\u011fi talimatlar esas al\u0131nmal\u0131d\u0131r.<\/p>\n<ul>\n<li><strong>Cinsel ili\u015fki veya ejak\u00fclasyon:<\/strong> Testten en az 48 saat \u00f6nce ka\u00e7\u0131n\u0131lmal\u0131d\u0131r.<\/li>\n<li><strong>Bisiklet s\u00fcrme:<\/strong> Testten 48 saat \u00f6nce yo\u011fun bisiklet s\u00fcrmekten ka\u00e7\u0131n\u0131lmal\u0131d\u0131r.<\/li>\n<li><strong>Parmakla rektal muayene (DRM):<\/strong> Muayeneden en az 1 hafta sonra kan verilmelidir.<\/li>\n<li><strong>Prostat biyopsisi:<\/strong> Biyopsiden en az 6 hafta sonra kan verilmelidir.<\/li>\n<li><strong>Prostat masaj\u0131, sistoskopi, kateterizasyon:<\/strong> Bu i\u015flemlerden sonra en az 1-2 hafta beklenmelidir.<\/li>\n<li><strong>\u0130la\u00e7lar:<\/strong> 5-alfa red\u00fcktaz inhibit\u00f6rleri (finasterid, dutasterid) PSA de\u011ferini yar\u0131 yar\u0131ya d\u00fc\u015f\u00fcrebilir; hekim bilgilendirilmelidir.<\/li>\n<\/ul>\n<p>Kullan\u0131lan ila\u00e7lar, takviyeler, yak\u0131n d\u00f6nemde ge\u00e7irilen hastal\u0131klar ve e\u015flik eden kronik durumlar sonucun yorumlanmas\u0131n\u0131 etkileyebilece\u011fi i\u00e7in sa\u011fl\u0131k profesyoneli ile payla\u015f\u0131lmal\u0131d\u0131r.<\/p>\n<h2>Total PSA (Prostat Spesifik Antijen Total) Testi Nas\u0131l Yap\u0131l\u0131r?<\/h2>\n<p>Total PSA (Prostat Spesifik Antijen Total) testi, uygun biyolojik \u00f6rnek al\u0131nd\u0131ktan sonra laboratuvar\u0131n belirledi\u011fi y\u00f6ntemle \u00e7al\u0131\u015f\u0131l\u0131r. Numunenin do\u011fru zamanda, uygun kapta ve uygun ta\u015f\u0131ma ko\u015fullar\u0131nda ula\u015ft\u0131r\u0131lmas\u0131 test kalitesi a\u00e7\u0131s\u0131ndan \u00f6nem ta\u015f\u0131r.<\/p>\n<ul>\n<li><strong>Numune T\u00fcr\u00fc:<\/strong> Serum<\/li>\n<li><strong>Numune Kab\u0131:<\/strong> Sar\u0131 Kapak<\/li>\n<li><strong>\u00c7al\u0131\u015fma G\u00fcn\u00fc:<\/strong> Her g\u00fcn<\/li>\n<li><strong>\u00d6nemli Kriter:<\/strong> \u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r.<\/li>\n<li><strong>Raporlama Tarihi:<\/strong> Ayn\u0131 g\u00fcn 18:00<\/li>\n<\/ul>\n<ul>\n<li>Koldan ven\u00f6z kan \u00f6rne\u011fi al\u0131n\u0131r (serum t\u00fcp\u00fcne).<\/li>\n<li>\u0130\u015flem birka\u00e7 dakika s\u00fcrer.<\/li>\n<li>Sonu\u00e7lar genellikle ayn\u0131 g\u00fcn veya ertesi g\u00fcn \u00e7\u0131kar.<\/li>\n<\/ul>\n<p>Baz\u0131 durumlarda \u00f6rnek kalitesi, numune miktar\u0131, ta\u015f\u0131ma s\u00fcresi veya teknik tekrar gereksinimi raporlama s\u00fcresini ve sonucun g\u00fcvenilirli\u011fini etkileyebilir.<\/p>\n<h2>Total PSA (Prostat Spesifik Antijen Total) Testi Ka\u00e7 G\u00fcnde \u00c7\u0131kar?<\/h2>\n<p>Mevcut laboratuvar bilgisine g\u00f6re bu test i\u00e7in raporlama s\u00fcresi: <strong>Ayn\u0131 g\u00fcn 18:00<\/strong> \u015feklindedir.<\/p>\n<p>Numunenin kabul zaman\u0131, laboratuvar\u0131n \u00e7al\u0131\u015fma plan\u0131, resmi tatiller veya gerekti\u011finde tekrar \u00e7al\u0131\u015fma gibi etkenler sonucu etkileyebilece\u011fi i\u00e7in en g\u00fcncel bilgi rapor tarihi \u00fczerinden de\u011ferlendirilmelidir.<\/p>\n<h2>Referans De\u011ferleri ve Sonu\u00e7lar\u0131n De\u011ferlendirilmesi<\/h2>\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Ya\u015f Grubu<\/th><th>De\u011fer<\/th><\/tr><\/thead><tbody><tr><td>40-49 ya\u015f<\/td><td>0 \u2013 2.5 ng\/mL<\/td><\/tr><tr><td>50-59 ya\u015f<\/td><td>0 \u2013 3.5 ng\/mL<\/td><\/tr><tr><td>60-69 ya\u015f<\/td><td>0 \u2013 4.5 ng\/mL<\/td><\/tr><tr><td>70-79 ya\u015f<\/td><td>0 \u2013 6.5 ng\/mL<\/td><\/tr><tr><td>Genel e\u015fik<\/td><td>0 \u2013 4.0 ng\/mL<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<p>> Not: Ya\u015fa \u00f6zg\u00fc referans de\u011ferleri kullan\u0131lmas\u0131 \u00f6nerilir. Referans de\u011ferleri laboratuvara g\u00f6re farkl\u0131l\u0131k g\u00f6sterebilir.<\/p>\n<p>Referans bilgileri; kullan\u0131lan y\u00f6ntem, ya\u015f grubu, biyolojik \u00f6rnek tipi ve laboratuvar standard\u0131na g\u00f6re de\u011fi\u015febilece\u011finden, rapor \u00fczerinde yer alan laboratuvar yorumu esas al\u0131nmal\u0131d\u0131r.<\/p>\n<h2>Total PSA (Prostat Spesifik Antijen Total) Sonucu Nas\u0131l Yorumlan\u0131r?<\/h2>\n<p>Test sonucu tek ba\u015f\u0131na kesin tan\u0131 koydurmaz. Sonu\u00e7; klinik bulgular, di\u011fer laboratuvar verileri ve gerekli g\u00f6r\u00fcld\u00fc\u011f\u00fcnde ek incelemeler ile birlikte de\u011ferlendirilir.<\/p>\n<h3>Y\u00fcksek PSA D\u00fczeyleri<\/h3>\n<p><strong>Malign nedenler:<\/strong><\/p>\n<ul>\n<li>Prostat kanseri<\/li>\n<\/ul>\n<p><strong>Benign nedenler:<\/strong><\/p>\n<ul>\n<li>Benign prostat hiperplazisi (BPH)<\/li>\n<li>Prostatit (prostat iltihab\u0131)<\/li>\n<li>\u0130drar yolu enfeksiyonu<\/li>\n<li>Prostat masaj\u0131 veya parmakla rektal muayene<\/li>\n<li>Ejak\u00fclasyon<\/li>\n<li>Uzun s\u00fcreli bisiklet s\u00fcrme<\/li>\n<li>Prostat biyopsisi veya cerrahi sonras\u0131<\/li>\n<li>\u0130leri ya\u015f<\/li>\n<\/ul>\n<h3>PSA Gri B\u00f6lge (4-10 ng\/mL)<\/h3>\n<ul>\n<li>Bu aral\u0131kta prostat kanseri olas\u0131l\u0131\u011f\u0131 %25-30 civar\u0131ndad\u0131r.<\/li>\n<li>Serbest PSA \/ Total PSA oran\u0131 bu aral\u0131kta ay\u0131r\u0131c\u0131 tan\u0131da \u00f6nemlidir.<\/li>\n<li>PSA dansitesi ve PSA velositesi ek de\u011ferlendirme parametreleridir.<\/li>\n<\/ul>\n<h3>PSA ile \u0130lgili Kavramlar<\/h3>\n<ul>\n<li><strong>PSA velositesi:<\/strong> Y\u0131ll\u0131k PSA art\u0131\u015f h\u0131z\u0131. >0.75 ng\/mL\/y\u0131l art\u0131\u015f \u015f\u00fcphe uyand\u0131r\u0131r.<\/li>\n<li><strong>PSA dansite:<\/strong> PSA de\u011ferinin prostat hacmine oran\u0131.<\/li>\n<li><strong>PSA doubling time (ikiye katlama s\u00fcresi):<\/strong> N\u00fcks takibinde \u00f6nemli; k\u0131sa s\u00fcre agresif hastal\u0131k d\u00fc\u015f\u00fcnd\u00fcr\u00fcr.<\/li>\n<\/ul>\n<h3>Tedavi Sonras\u0131 Takip<\/h3>\n<ul>\n<li><strong>Radikal prostatektomi sonras\u0131:<\/strong> PSA \u00f6l\u00e7\u00fclemez d\u00fczeye d\u00fc\u015fmelidir (<0.2 ng\/mL). Yeniden y\u00fckselme biyokimyasal n\u00fcks\u00fc g\u00f6sterir.<\/li>\n<li><strong>Radyoterapi sonras\u0131:<\/strong> En d\u00fc\u015f\u00fck de\u011ferden 2 ng\/mL y\u00fckselme n\u00fcks kabul edilir (Phoenix kriterleri).<\/li>\n<\/ul>\n<h3>\u00d6nemli Notlar<\/h3>\n<ul>\n<li>Y\u00fcksek PSA her zaman kanser anlam\u0131na gelmez; d\u00fc\u015f\u00fck PSA kanseri tamamen d\u0131\u015flamaz.<\/li>\n<li>Tarama karar\u0131 hasta ile payla\u015f\u0131larak verilmelidir (ortak karar verme).<\/li>\n<li>5-alfa red\u00fcktaz inhibit\u00f6rleri kullanan hastalarda PSA de\u011feri 2 ile \u00e7arp\u0131larak ger\u00e7ek de\u011fer tahmin edilir.<\/li>\n<\/ul>\n<p>\u00d6zellikle s\u0131n\u0131rda, d\u00fc\u015f\u00fck d\u00fczeyli veya beklenmeyen sonu\u00e7larda klinik korelasyon gerekir. Gerekti\u011finde tekrar test, panel de\u011ferlendirmesi veya ek laboratuvar incelemeleri planlanabilir.<\/p>\n<h2>Testin S\u0131n\u0131rl\u0131l\u0131klar\u0131<\/h2>\n<p>Her laboratuvar testinde oldu\u011fu gibi bu incelemenin de baz\u0131 s\u0131n\u0131rl\u0131l\u0131klar\u0131 vard\u0131r. Sonu\u00e7; \u00f6rnek kalitesi, \u00f6rnekleme zaman\u0131, ta\u015f\u0131ma ko\u015fullar\u0131 ve klinik ba\u011flamdan etkilenebilir.<\/p>\n<ul>\n<li>Tek bir laboratuvar sonucu, klinik \u00e7er\u00e7eve d\u0131\u015f\u0131nda eksik yorumlanabilir.<\/li>\n<li>Uygun olmayan numune kalitesi sonucun g\u00fcvenilirli\u011fini azaltabilir.<\/li>\n<li>Gerekti\u011finde ek testler olmadan tek ba\u015f\u0131na karar vermek yan\u0131lt\u0131c\u0131 olabilir.<\/li>\n<\/ul>\n<h2>Olas\u0131 Riskler<\/h2>\n<p>Risk \u00e7o\u011funlukla numune alma ve numune y\u00f6netimi s\u00fcreci ile ili\u015fkilidir. Testin kendisinden \u00e7ok, \u00f6rne\u011fin al\u0131nmas\u0131 ve uygun ko\u015fullarda \u00e7al\u0131\u015f\u0131lmas\u0131 \u00f6nem ta\u015f\u0131r.<\/p>\n<ul>\n<li>Kan al\u0131m\u0131na ba\u011fl\u0131 hafif a\u011fr\u0131, morarma veya \u015fi\u015flik olabilir.<\/li>\n<li>Testin kendisine ba\u011fl\u0131 ciddi bir risk yoktur.<\/li>\n<li><strong>A\u015f\u0131r\u0131 tan\u0131 (overdiagnosis) riski:<\/strong> PSA taramas\u0131 yava\u015f ilerleyen, klinik olarak anlams\u0131z kanserlerin tan\u0131nmas\u0131na ve gereksiz tedavilere yol a\u00e7abilir.<\/li>\n<li><strong>Yanl\u0131\u015f pozitif:<\/strong> BPH ve prostatit gibi benign durumlarda y\u00fckseklik gereksiz biyopsiye neden olabilir.<\/li>\n<li><strong>Yanl\u0131\u015f negatif:<\/strong> Normal PSA prostat kanserini tamamen d\u0131\u015flamaz.<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Total PSA (Prostat Spesifik Antijen Total) Laboratuvar Bilgileri Yeni Kod: BIO6090 SUT Kodu: L106280 Eski Kod: HR0067 Kategori: Biyokimya Numune T\u00fcr\u00fc: Serum Numune Kab\u0131: Sar\u0131 Kapak \u00c7al\u0131\u015fma G\u00fcn\u00fc: Her g\u00fcn \u00d6nemli Kriter: \u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r. Raporlama Tarihi: Ayn\u0131 g\u00fcn 18:00 Total PSA (Prostat Spesifik Antijen Total) [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":0,"parent":5,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"test_category":"Biyokimya","test_kodu":"BIO6090","numune_turu":"Serum","numune_kabi":"Sar\u0131 Kapak","calisma_gunu":"Her g\u00fcn","onemli_kriter":"\u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r.","raporlama_tarihi":"Ayn\u0131 g\u00fcn 18:00","numune_red_kriterleri":"","aktarim_kodu":"","loinc_kodu":"","sut_kodu":"L106280","akredite":"","numune_miktari":"","alternatif_ornek":"","numune_alinma_sekli":"","stabilite_ozellikleri":"","calisma_yontemi":"","test_bilgisi":"","footnotes":""},"class_list":["post-3236","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/3236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/types\/page"}],"replies":[{"embeddable":true,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/comments?post=3236"}],"version-history":[{"count":5,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/3236\/revisions"}],"predecessor-version":[{"id":8973,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/3236\/revisions\/8973"}],"up":[{"embeddable":true,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/5"}],"wp:attachment":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/media?parent=3236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}